← 返回

T 细胞中的功能性 CRISPR 筛选为癌症免疫治疗揭示了新机遇

英文原题:Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.

查看英文原题

Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies.

PubMed 2024/04/05(内容时间) Mol Cancer Q1 · IF 42.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

T细胞是肿瘤免疫和癌症免疫治疗的基本组成部分,已取得巨大进展并彻底改变了癌症治疗模式。然而,近期研究揭示了肿瘤微环境中T细胞失调的困境以及癌症免疫治疗疗效受损的问题。CRISPR筛选能够对T细胞中的基因功能进行无偏倚探究,并已揭示了T细胞生命周期中的功能决定因素、基因调控网络和细胞间相互作用,从而为革新癌症免疫治疗提供了机会。在本综述中,我们简要描述了T细胞在成功癌症免疫治疗中的核心作用,全面总结了T细胞中CRISPR筛选的研究,阐述了控制T细胞活化、增殖、命运决定、效应功能和耗竭的由此发现的主控基因,并重点介绍了广泛参与T细胞应答多个分支的基因(BATF、PRDM1和TOX)和信号级联(JAK-STAT和NF-κB通路)。

总之,本综述弥合了从发现元素基因到T细胞活动特定过程与在全局T细胞生命周期中理解这些基因之间的差距,加深了对肿瘤免疫中T细胞生物学的理解,并概述了可能促进癌症免疫治疗在临床中开发与实施的CRISPR筛选资源。

展开英文摘要原文

T cells are fundamental components in tumour immunity and cancer immunotherapies, which have made immense strides and revolutionized cancer treatment paradigm.

However, recent studies delineate the predicament of T cell dysregulation in tumour microenvironment and the compromised efficacy of cancer immunotherapies. CRISPR screens enable unbiased interrogation of gene function in T cells and have revealed functional determinators, genetic regulatory networks, and intercellular interactions in T cell life cycle, thereby providing opportunities to revamp cancer immunotherapies.

In this review, we briefly described the central roles of T cells in successful cancer immunotherapies, comprehensively summarised the studies of CRISPR screens in T cells, elaborated resultant master genes that control T cell activation, proliferation, fate determination, effector function, and exhaustion, and highlighted genes (BATF, PRDM1, and TOX) and signalling cascades (JAK-STAT and NF-κB pathways) that extensively engage in multiple branches of T cell responses.

In conclusion, this review bridged the gap between discovering element genes to a specific process of T cell activities and apprehending these genes in the global T cell life cycle, deepened the understanding of T cell biology in tumour immunity, and outlined CRISPR screens resources that might facilitate the development and implementation of cancer immunotherapies in the clinic.

论文信息

作者
Xiang M、Li H、Zhan Y、Ma D、Gao Q、Fang Y
第一作者单位
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.China
通讯作者单位
Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. tongjify@163.com.China
文献类型
综述 · 非美国政府资助研究
期刊
Molecular cancer2024 Apr 5
原文标识
PubMed 38581063 · DOI 10.1186/s12943-024-01987-z